NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (“ImmunityBio”…
ImmunityBio stock surges on $100M financing deal…
New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff…
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race…
ImmunityBio shares plunge after FDA warning over misleading ads…
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance…
ImmunityBios Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.…
On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.…
EU-Zulassung als Gamechanger: Anktiva bekommt grünes Licht in Europa – die ImmunityBio-Aktie explodiert (zeitweise +40 %) und steht nach der…
On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal…
ImmunityBio stock rises after productive regulatory talks with Saudi FDA…
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.…
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks Jim Cramer talked about, along with market froth. When a caller asked…
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the companys heavily-shorted stock.…
Revolutionäre Immunmodulation als Kernkompetenz ImmunityBio Inc. (IBRX) hat sich von einem klassischen Biotech-Forschungsunternehmen zu einem kommerziellen Akteur im Bereich der…
…
It has been an incredible week of positive news for ImmunityBio.…
These are the stocks posting the largest moves in premarket trading.…
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses…
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This…
ImmunityBio (IBRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
ImmunityBio Inc. (IBRX) (i.) ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Next-Generation-Therapien und Impfstoffen konzentriert, die das natürliche…
ImmunityBio shares surge following progress in FDA discussions…
…
Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the…
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
…
ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the…
…
ImmunityBio shares target raised by Piper Sandler on potential approval…
Die Bekämpfung von Krebs ist zentrales Thema für viele Biotech-Unternehmen. ImmunityBio, hinter der der bekannte Investor, Forscher und Erfinder Patrick…